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Abstract 
Thalassemia has become major health problem among developing countries. 
Genetic background which contains enormous mutations and variations have lead 
in clinical problem differences. 
The genetic basis of thalassemia, beta specifically, is mutations of the gene 
encoding the β chain of the hemoglobin (Beta-Globin, HBB). However, today it is 
known that abnormalities in this gene do not necessarily determine the clinical 
appearance of β thalassemia patients.Currently there are several genetics and non 
genetics factor that are influenceclinical manifestation such as the type of β globin, 
gene mutation, co-inheritance with α thalassemia and HPFH and also non genetic 
factor that worsen the clinical symptom i.e infection,nutritional status, and 
oxidation state such as iron overload. Several genetic studies are still notable to 
explain the cause of inconsistency between genotype and phenotype of β 
thalassemia. 
A set of genes that can modify the primary b thalassemia disorder has be 
founded. Secondary modifier contains genes that have been associated with 
elevated levels of HbF or continuous production of γ chainand improvement ratio 
of α / non α globin chain. The genes involved are HBA, HBG, BCL11A, HBS1L-
MYB and other cofactor genes regulating erythropoiesis. Tertiary genetic modifier 
comes from other genes related to the disease severity including iron metabolism, 
redox activity, and clinical complications. The review aims to provide the latest 
updates regarding the known β thalassemiamodifier genes and some other genes 
involved in the changes of the clinical manifestations. 
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INTRODUCTION 
Thalassemia is a hereditary hemolytic disease with 
the highest prevalence and incidence in the world. It is 
one of the most serious health problems given that 
thousands of children suffer from it each year. 
Thalassemia is most prevalent in the areas known as 
the Thalassemia Belt, such as the Mediterranean, 
Middle East, Southern Asia, China Peninsula, 
Southeast Asia, and Pacific Islands1. Recent reports 
suggested that Thalassemia has rapidly spread to 
America, Europe, and Australia due to migration and 
inter-marriage of different ethnic groups. The World 
Health Organization (WHO) estimates that 7% of the 
global populations (80 – 90 million people) are 
carriers of β thalassemia where most of them from 
developing countries.  
 
The high frequency of Thalassemia in these 
regions is strongly associated with the spread of 
Plasmodium falciparum. Of the population who are 
endemic with malaria, about 3 – 40 % carries the 
variant hemoglobin, with thalassemia major 
prevalence at about 0.3 – 25 per 1000 births. The 
literature suggests that from the numbers, only about 
200,000 patients with the major symptoms of 
Thalassemia that are registered and receive regular 
governance2. The data from Indonesia reported that β 
thalassemia carriers were 3 - 5%population and in 
some areas this numbers even reaches 10%. It is 
estimated that there will be2500 children born with 
thalassemia annually. This number is far below the 
real number foundin the population. This discrepancy 
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is thought to be caused by several factors including 
thevariety of clinical features that range from 
extremely mild symptoms that do not 
requiretransfusion to the severe ones that need regular 
transfusion.3 
 
Molecular Pathophysiology  
1. Primary Modifier of β thalassemia 
It has been shown that clinical heterogeneity in β 
thalassemia primary is caused by variations of genetic 
lesions in β globin gene. Patient severity and the 
amount of produced globin protein are directly 
associated with a mutation on the β globin gene.4,5 
More than 300 point mutations in β globin gene have 
been identified and deletion is very rare. However, 
genotype variability in  β globin gene only is often not 
enough to explain the different phenotypes when the 
patients show the same genotype6. Wahidiyat, 2009 
had reported a family who had two βthalassemia /HbE 
children, one of them need 6-8 timestransfusion per 
years, while the other does not require transfusion. 
The hemoglobin and DNA analysis showed the same 
mutation, β+ severe thalassemia/HbE was present in 
both children. This case shows how patients with the 
samegenetics and non genetics (environmental) 
factors may show different clinical manifestations.3 
β thalassemia occurs due to the disappearance of 
the β globin chain (β thalassemia0) or the disruption of 
β chain (β thalassemia+) on blood globin structure. In 
β thalassemia, there is an imbalance of production 
between the globin α chain and globin β chain that 
would normally form A hemoglobin (Adult).7 The 
disruption in the synthesis of β globin in β thalassemia 
patients lead to an excess of the globin α chain, so 
there is  α chain precipitation inside the red blood cell 
precursor in the bone marrow and also in the 
derivatives of peripheral circulation. The erythroid 
nuisance induces an ineffective erythropoiesis shown 
by the proliferation of bone marrow cells and extra 
medullary erythropoiesis.8,9 Furthermore, products 
like heme, hemin, hemichrome, and loose iron can 
cause a pathological change in red blood cells due to 
oxidative damage of the cell membrane that leads to 
apoptosis. A further study suggested that the erythroid 
precursor of a Thalassemia patient showed 3-4 times 
higher apoptosis level than the erythroid in a normal 
person.10 Mechanism, able to reduce the a/non a chain 
imbalance is the co-inheritance with a thalassemia, 
continuous production of y chain which binding the 
excess of achain result in a persistent fetal 
haemoglobin (HbF) production 
The clinical phenotypes of ß thalassemia patients 
vary depending on the requirement of blood 
transfusion. The phenotype is associated with the 
degree of imbalance and the surplus of the globin α 
and β chain. This clinical spectrum involves many 
factors, including the type of mutation in the β gene as 
a primary modifier, a secondary modifier that leads to 
the improvements of the balance ratio of α and β 
globin chain, and also a tertiary modifier which is 
both genetic and non-genetic that ameliorates or 
aggravates with the disease appearances and 
complication.11 
 
β Globin Mutations. 
Clinical variability of β thalassemia patients 
correlates with the mutation type contained in the 
globin β gene. Allele classification is distinguished 
into two major classes that are a severe allele with 
total absence of the globin chain, and the mild allele 
which produces a globin chain that is inheritable. The 
alleles are notated as β0 and β+, respectively. Most of 
the mutations that cause these types are point 
mutations. Another type involves a deletion.12 
Today, more than 300 unique mutations have been 
well characterized. There are four known major 
mutants of β thalassemia: a promoter mutant, RNA 
splicing, RNA capping/tailing mutant, and a 
translation mutant.6 Another form of molecular 
abnormality is a frameshift mutation that can 
transform the reading frame, thus resulting in a short 
and unstable polypeptide or the formation of a codon 
stop (nonsense mutation) that results in a premature 
termination of translation process.13 A variation of 
these kind mutations will affect on the first 
transfusion time, transfusion requirements, and 
clinical appearances in the patient’s life.14 
The mutation that interferes with the transcription 
process can happen in the 5’ untranslated region (5’ 
UTR) of the globin β gene as well as in the proximal 
CACC box. An example of the mutation is -90 C>T, -
88 C>T, -88 C>A. Moreover, the mutation can also 
happen in the TATA box region such as -31 A>G and 
-30 T>A. Generally, the mutations interfere with the 
production of the globin chain on a basic level thus 
suggests a picture of mild clinical diagnosis of β+ or 
even silent β++.15 
The mutation that involves the RNA splicing process 
can happen on the splice donor site such as IVS2-2-T 
or splice acceptor site such as IVS2-850 G>T that 
leads to a clinical picture of severe Thalassemia (β0) 
due to non-formation of the normal RNA. The 
mutation that is located between those areas can lead 
to the decrease of varied RNA which raises the 
Thalassemia phenotype from mild to severe. One of 
the mutations is IVS2 -5 G>T. A variant structure of 
HbE (Cd26 GAG>AAG) is the general form in the 
Southeast Asian population which can result in the 
mild type (β+) Thalassemia phenotype because it 
could activate cryptic splicing of the GTGGTGAGG 
donor in codon 24-27 of exon 1. The activation which 
causes the normal production of HbE is reduced so the 
clinical manifestation of Thalassemia can occur.16  
The mutation that involves the start codon can 
interfere with the initiation of the transcription process 
and results in the β0 phenotype; for instance, the 
ATG>AGG mutation. The mRNA elongation process 
can be interrupted by nonsense mutation like Cd17 
AAG>TAG or a frameshift mutation like Cd41/42 – 
TTCT. These mutations cause a premature 
termination of the mRNA and result in a severe 
Thalassemia phenotype (β0). Some of the β+ and β++  
14 
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Figure 1. β Globin Gene and Common β Thalassaemia Mutation 
β globin gene is built from 3 exons and 2 intervening sequences (introns). The majority of β gene mutations are located in 
front of the gene and predominantly by point mutations. Upstream mutations may affect TATA box region and 5 UTR 
including start codon ATG. Exon 1, exon 2 and intron (IVS/intervening sequences) 1 are the most prevalence mutations in 
β gene, while the rest are less common. 
phenotypes are caused by a mutation in the 
polyadenylation region (AATAAA) at 3’ position in 
the end of the globin β gene that can destabilize the 
mRNA chain. An example of this mutation is 
AATAAA>CATAAA.17 The full set of common 
mutations in β thalassemia is depicted in figure 1. 
Some of the mutants show a dominant reduction 
nature.13 On the mutant that produces a premature 
termination codon (PTC) of mRNA that is caused by 
the frameshift mutation or nonsense mutation, this 
mRNA will be degraded by nonsense-mediated 
mRNA decay (NMD) so the presence of the mRNA is 
at a minimum level.18 If the PTC mutation occurs in 
exon 3 of the globin β gene, NMD does not function 
well and abandons the chain, so the mRNA can be 
translated and produces variant globin protein that can 
cause a precipitation in the erythroid precursor.6  
 
2. Secondary Modifier of β thalassemia 
The clinical pictures of Thalassemia that are 
caused by a primary mutation of the β globin can be 
modified by another gene outside the β globin gene. 
This secondary genetic factor modifies the 
Thalassemia phenotype by repairing the imbalance of 
the globin chain and the surplus of globin chain. HbF 
which is normally expressed in the fetus period is able 
to modify the clinical picture by binding the surplus of 
α chain on β thalassemia.11,19 The surplus of an α 
chain on β thalassemia can cause a precipitation of the 
erythrocyte membrane as a hallmark of the disease 
that can be modified by some conditions like a 
coinheritance with an α mutation and the increase of 
HbF.20,21  
 
α/β Globin Ratio Modifier. 
It has been reported that homozygous β 
thalassemia or a heterozygote compound that carries a 
deletion allele of α gene show less severe phenotype. 
The mechanism of this modification effect depends on 
the severity level of the mutation allele type on the β 
gene and the number of functionalities of the α gene.15 
The coinheritance from a single deletion of the α gene 
on β thalassemia has a minimum impact while the 
deletion of two α genes shows a less severe 
phenotype.22 The occurrence of an α gene deletion 
causes a balance between α and β chains on β 
thalassemia and the patient recovers. With a 
heterozygote β thalassemia patient, a single deletion 
of the α gene shows an absence of hypochromic 
microcytic blood pictures, while the addition (extra 
copy) to the α gene causes a more severe clinical 
picture in β thalassemia patients. Some of the 
heterozygote β thalassemia patients with a triplication 
of α genes (α α α / α α α) show a phenotype spectrum 
from asymptomatic to intermediate Thalassemia.23 
Another study also reported that quadriplication of α 
genes in simple heterozygosis and in carriers of 
suspected silent β thalassemia, may result in 
symptomatic thalassemia.24 The recent reports shows 
that this kind of genotype constitution is not rare in 
case of thalassemia intermedia.25 The balance 
abnormalities of α and β chains on β thalassemia are 
also related with major α globin gene regulator. 
Homozygous deletion on these regulator may produce 
Hb H disease appearance,26,27 but in coinheritance 
with β thalassemia could modify α and β chain ratio, 
impacting to a better condition.28 
 
Increasing of HbF as Modifier 
The ratio of α and β chains on β thalassemia can 
also be modified by an increase of HbF production. 
Though in normal adults the production of HbF is 
stopped when they were born, the HbF is still 
minimally produced (±1 %). In the case of β 
thalassemia, HbF is relatively increased due to the 
selective survival from  the erythroid  precursor that  
synthesizes the γ chain. A normal adult has 0.5 – 1% 
of HbF which is concentrated at F-cells (3-7% of 
erythrocyte total). However, the β thalassemia patients 
have a different ability in terms of the number of 
synthesized γ chains.13 
The enhancement of HbF in the adult can occur in 
the cases of Hereditary Persistence of Fetal 
Hemoglobin (HPFH) and through the Quantitative 
Traits Locus (QTL). The deletion of seven areas 
within the locus of β globin has been characterized 
and associated with HPFH. These HPFH deletions 
show the enhancement of HbF by 30% of total 
hemoglobin expressed on all of the erythrocytes (pan-
cellular HbF).29 The basis mechanism of the 
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abnormality may be caused by the inability of normal 
γ globin diversion due to juxtaposition from the 
enhancer distal element in the proximal area of the γ 
globin gene as a result of the deletion.17   
Different from the deletion HPFH type, where 
both Gγ and Aγ genes run into overexpression, non-
deletion HPFH expresses only a single globin γ gene. 
The identification of a point mutation in a non-deleted 
HPFH case is 5 mutation types that have been found 
on GC rich -200 G γ, -202 C>T, -198T>C, -196C>T, -
195 C>G from A γ gene.30 HPFH expressed only a 
single globin y chain is limited to XmnlGγ 
polymorphism. Pathomechanism of HbF enhancement 
on the non-deletion HPFH is still a controversial 
topic. The affinity enhancement of Spl protein is 
reported to have a correlation with the HbF 
enhancement in the case of HPFH on several point 
mutations that are -202 C>G, -198 T>C and -195 C>G 
.31 Recent studies found that this kind of mutation is a 
de novo binding site from the Stage Selector Protein 
(SSP) which is a protein complex that causes an 
adhesion with the proximal promoter, while -198T>C 
creates a novel CACCC box in the globin A γ 
promoter.32 
In addition to HPFH, the increased production of 
HbF involves genes that are included in the 
Quantitative Traits Locus (QTL) of HbF Inducer. 
There are at least three main loci that are associated 
with the increased production of HbF and affect the 
phenotype of β thalassemia patients. Those loci are Gγ 
promoter, chromosome 6q, and chromosome 2.11 
 
Quantitative Traits Locus (QTL) of XmnI, 
BCL11A, and HBS1L-MYB   
A -158 C>T point mutation on Gγ promoter, noted 
as XmnIlocus, is known to play a role in the relative 
overproduction of HbF. In a non-anemic population in 
Northern Europe, XmnI inside of the locus is 
correlated with the increase of HbF on the level of 13-
32 % F cells.33 Another study suggested that the XmnI 
locus played a role in determining the prognosis in 
Sickle Cell Disease.34 A more detailed study from 
Lettre et al.35 suggested that SNP rs7482144 (XmnI 
locus) explained the 2.2 % increase in HbF production 
variety in an SCD case. In some cases of β 
thalassemia, the SNP suggests a Linkage 
Disequilibrium with mutations like 6 –A codon and 8 
–AA codon that is consistently associated with the 
increase of HbF, resulting in an intermediate 
Thalassemia phenotype.11 Another study suggests that 
the XmnI genotype (+/+) can be used as a phenotype 
predictor of β thalassemia cases.36 However, the role 
of SNP rs7482144 for the relative increase of HbF is 
inconsistent in normal adults and heterozygote 
Thalassemia.37 
A central role of SNP rs7482144 has been 
confirmed in Genome Wide Association Study 
(GWAS). In a European study, the traits variance of 
the locus is 10.2 %.38 The XmnI locus is further 
reported as having a role in the increase of HbF in 
intermediate Thalassemia.36 In India, the genotype 
(+/+) suggests a meaningful correlation with the 
clinical occurrence of β thalassemia patient,39 while 
the population study on heterozygote Thalassemia 
patients in China suggests that the XmnI locus is 
associated with the increase of 9 % HbF and 13 % of 
F-cell.40 However, in the African population in 
America with SCD, SNP rs10128556 is more strongly 
correlated than the rs7482144 / XmnI, indicating that 
the XmnI locus in this ethnic group is not a causal 
variant.41 The data from Indonesia reported that 
genotypes (-/-) and (+/) of the XmnI locus is not 
related with the absolute amount of HbF in HbE/ β 
thalassemia patients.42 The same group reported that β 
thalaseemia mutation type is not a factor that 
influence clinical manifestation, apartfrom the IVSl-nt 
5 (G>C) that is related to severe clinical features, 
co-inheritance of a globin deletion type 3,7 kb (co/o-) 
is related to mild clinical manifestation, while 
α­globin chain triplication did not exist both mild and 
severe groupsand therefore its relation with clinical 
manifestation could not be assessed. Study also 
showed that Xmnl heterozygote polymorphisms 
(polymorphism in-150°y globin gene, C>T) 
werefound both in the mild and severe groups, 
therefore this kind of polymorphism is not afactor that 
influences clinical manifestations. From three SNPs, 
only bg200 was related to clinical manifestations the 
CC genotype atSNP bg200 is related to low HbF level 
and severe clinical manifestations, and have 4.15times 
greater risk of having severe manifestation that those 
without. 
In addition to the β gene cluster, a study of Asian-
Indian patients with β thalassemia that was 
accompanied by a sample segregation with rising 
HbF, found that the locus of the 6q23-q24 
chromosome is correlated with the increase of HbF. 
The locus shows an association where the genome-
wide linkage analysis (GWLA) is meaningful in the 
less severe β thalassemia phenotype.11 Further studies 
suggest that the areas along 1.5 Mb in 6q23-q24, there 
is an intergenic area of HBS1L and MYB genes.38,43,44 
The locus is associated with ~19 % of the natural 
variety of the population in Europe.38 The research 
found that 3 SNPs were the main markers that have 
the highest correlation to HbF and F-cells level: 
rs9399137, rs5209090, and rs6929404. A Population 
study in China and African-American suggest that the 
two main SNPs correlated with this are rs9399137 and 
rs7775698.45 Homozygosity for the 3-bp deletion in 
HMIP and heterozygosity for the HbH a-thalassaemia 
mutation in HBA2 were also reported as the two 
genetic determinants found only in the asymptomatic 
of FSC8 homozygote twins and not found in other 
FSC8 typical transfusion dependent patients.46. 
With the marker from BCL11A rs4671393, 
HBS1L-MYB rs9399137, rs28384513, and 
rs4895441, and rs7482144 XmnI locus, Lettre et al.34 
suggested that SNPs is responsible for >20 % of HbF 
phenotype varieties and is associated with a better 
clinical prognosis. Genetic variety in the area of 
HBS1L-MYB is significantly different between the 
individual with high HbF and normal individuals.41 
The basis mechanism from the situation is possibly 
related with the role of MYB in the erythropoiesis 
process. MYB gene overexpression inhibits the γ 
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globin in erythroleukemia cells. Furthermore, research 
data suggests that the low level of MYB protein in the 
initiation of erythropoiesis is correlated with rising 
HbF levels.47 
The BCL11A locus in chromosome 2 is known to 
be associated with the increase of HbF based on the 
findings that the gene is responsible for the Hb 
transition mechanism.48,49 Fine mapping on the 
BCL11A locus in the African-American population 
with SCD found three independent SNPs that are 
related to HbF. Haplotype analysis (based on SNP) 
suggests that the haplotype in this locus describes a 
better phenotypic variance on the cumulative amount 
than the three SNPs when taken individually (18.1 vs. 
14.7 %).41  
The findings are confirmed in the normal 
population of Chinese and Thai descent carriers of β 
thalassemia50 and patients with sickle cell anemia 
from the USA, Brazil, and the UK.35 It was suggested 
that the SNP rs766432 minor allele (C) has the 
strongest association with the increase of HbF and F-
cell in the Chinese, Thai, and African-American 
populations50, while the SNP rs11886868 is associated 
with the increase of HbF in the Caucasian population 
in lower levels.51 The study on another population in 
China suggested that rs11886868 has a strong 
association with the increase of HbF in Thalassemia 
patients21, while in Thailand, rs766432 on BCL11A 
has a strong association to the increased level of HbF 
52, as well as in Indonesia.53 A very recent study found 
that the LRF/ZBTB7A transcription factor occupies 
fetal γ-globin genes and maintains the nucleosome 
density necessary for γ-globin gene silencing in 
adults, and that LRF confers its repressive activity 
through a NuRD repressor complex independent of 
the fetal globin repressor BCL11A.54 
Quantitative Traits Locus of HBG, BCL11A and 
HBS1L-Myb in ameliorating β thalassemia through 
elevating HbF have been known and ready to 
implement in thalassemia management. The 
Thalassemia Severity Score web-tool 
((http://tss.unica.it)is available now to calculate and 
predict the severity of clinical phenotype based on 
prominent marker; β type mutations, α deletion, 
HBG2:g.-158C>T, BCL11A rs1427407, BCL11A 
rs10189857, and HBS1L-MYB rs9399137. Validation 
of the model was conducted by Danjou and 
colleagues.55 
 
Element factors of EKLF, GATA, GDF11, GDF15, 
and AHSP  
The Kruppel-like factor 1 (KLF1), a key factor for 
primitive and definitive erythropoiesis has been 
reported to have significant rule in ameliorating 
clinical phenotype of β Thalassemia. Individual with a 
dominant missense mutation in the KLF1 zinc-finger 
domain has ineffective erythropoiesis picture leading 
to congenital diserythropoietic anemia (CDA).56 β 
Thalassemia patient who has this kind of mutation can 
be fall into severe condition. Conversely, there are 
sequence alterations that result in HFPH may actually 
ameliorate the disease severity. A high HbF levels of 
up to 40% of total hemoglobin (Hb) was already 
found in individual with compound heterozygotes for 
class 2 and 3 KLF1 .57  Recent study also reveal that 
class 2 or 3 KLF1 variants are associated with 
moderately increased levels of HbA2, making 
attention to β Thalassemia carrier screening 
program.58  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cofactor FOG-1 (freind of GATA-1) primarily 
regulates erythropoiesis and megakaryocytopoiesis. 
Mutations in the FOG-1 binding sites of its N-
terminal zinc finger are responsible for 
dyserythropoietic anemia with thrombocytopenia, 
facing to severe phenotype.59 It has been shown that 
elevated Epo production is associated with high levels 
of Jak2 phosphorylation. This kind action promotes 
escalation of erythroid progenitors which contribute to 
extramedullary hematopoiesis. Literature review of 
these studies proposed that acute administration of a 
Jak2 inhibitor (JAK2i) could reverse the 
splenomegaly in thalassemic patients avoiding the 
need for splenectomy.60 Other findings were also 
interesting. Growth differentiation factor 11 (GDF11), 
a factor responsible for rejuvenation of stem cell is 
promising. Ongoing clinical trial is showing 
amelioration of the anemia in NTDT patients and a 
potential reduction of the transfusion regimen in 
patients affected by β-thalassemia major.60 Another 
factor is GDF15. An abundant expression of GDF15 
inhibited hepcidin expression, contributing to iron 
overload process in thalassemia syndrome.61 Reducing 
GDF15 factor may decrease toxicity of iron and 
contribute to clinical improvement.  
Figure 2. Normal and β thalassemia condition 
A. Eryhtrocytes contains normal composition of globin 
chain; two β globin chains pair with four α globin chain. 
B. Mutation in β globin chain disrupt the balance of α/non 
α ratio. Improvement of the ratio could be achieved by 
decreasing trans acting factors (KLF1, Sox6, MYB, and 
BCL11A) or accelerating cis factor including HPFH and γ 
globin chain. In another side, decreasing α globin chain 
through deletion or increasing AHSP activation would be 
benefit for α/β ratio. 
17 
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Another genetic determinant reported as having a 
link with the milder phenotype of β Thalassemia is the 
α-hemoglobin-stabilizing protein (AHSP), the active 
molecular chaperon which binds to the free α chain. 
AHSP protein can act as a stabilizer for the α chain at 
the time of globin chain binding and prevents a 
precipitation.62 Mice knocked-down on AHSP protein 
have an abnormal red blood cell production and 
showed shorter lifespan, allegedly caused by a relative 
surplus of unused globin chains. Furthermore, the 
phenotype was aggravated upon testing with the 
intermediate Thalassemia genotype, corresponding to 
the loss of AHSP.63 
By using K562 cells, it was suggested that AHSP 
can be a candidate genetic modifier in thalassemia 
patients.64 It was also reported that an individual in 
Southern Asia with an AHSP mutation homozygote 
(Val56>Gly), in the initial year of life shows a clinical 
syndrome similar to a Thalassemia patient.65 Research 
on Thalassemia patients suggested that the effect of 
mutations or polymorphisms in AHSP is still 
controversial. Previous studies suggested that the 
mutation on the gene is not significantly associated 
with the severity of the β thalassemia patient 
population in China66  and Thailand.67  
 
3. Tertiary Modifier of β thalassemia 
The course of the Thalassemia clinical syndrome 
can be affected by many factors including genetics 
that are associated with a blood component, genetics 
outside of the blood component, or non-genetic 
conditions.68 The oxidative stress in Thalassemia 
patients occurs due to hemoglobin instability, the 
surplus of iron, and hemolysis. In normal conditions, 
red blood cells degrade the reactive oxygen species 
(ROS) through the superoxide dismutase (SOD), 
catalase (CAT), and glutathione peroxidase (GPx) 
activities.69,70 In the thalassemia cell, there is heme 
release that induces the amplification of the oxidative 
pathway. The excess iron can also act as a catalyst of 
fat peroxidase. Moreover, the hypochromic condition 
can cause an acceleration of the oxidative process due 
to a lessening of buffer protection by hemoglobins. It 
has been reported that the accumulation and auto-
oxidation from the unpaired globin α chain will 
produce superoxide (O2-) and hydrogen peroxide 
(H2O2) that leads to accelerated apoptosis and 
ineffective erythropoiesis.71 
Several studies reported that the oxidative activity 
is associated with the level of iron levels in the 
body.72 By using a curcuminoid as an antioxidant, 
Kalpravidh and colleagues suggested that 
malondialdehyde, superoxide dismutase, and GPx 
enzyme significantly decrease with 12 months of 
therapy. In these studies, it was reported that 
curcuminoid can also be an alternative iron chelator 
that can decrease the ferritin levels. The excess 
accumulation of iron can increase the free radicals in 
the circulation. An individual’s ability to parse is 
controlled by a genetic mechanism that is appropriate 
with the involved enzyme.73 
Glutathione and Catalase are two enzymes that 
initiated the regulation of the free radicals. 
Glutathione S transferase (GST) is a superfamily 
enzyme from multifactorial isoenzymes that play role 
in detoxification and excretion of toxic molecules. 
Evidence suggests that the expression level of GST is 
a key factor in determining the cell sensitivity in a 
wide spectrum towards the toxic chemicals.74 The 
enzyme is coded by 16 polymorphic genes that are 
divided into five classes: α (GSTA), π (GSTP), μ 
(GSTM), θ (GSTT), ζ (GSTZ).75 
GSTM1 and GSTT1 loci are very polymorphic 
and the deletion of both alleles (null genotype) 
eliminates the role of the enzyme and enhances the 
vulnerability towards oxidative stress.74 It was 
reported that GSTT1 and GSTM1 polymorphisms 
affect the degree of cardiac siderosis as one of the 
factors that causes death in Thalassemia patients.76 A 
“Null” genotype of the GST genes can lead to an 
enhancement of susceptibility to oxidative reactions, 
with the result of increased risk of tumor, prostates or 
cardiac disorders.77 As well as CAT (coding gene of 
Catalase enzyme) polymorphism in exon 9 on the 
rs769217 locus is allegedly associated with low 
activity of Catalase enzyme which result in lower 
protection of catalase against free radicals.78  
Osteopenia and osteoporosis are some of key 
factors in the morbidity of Thalassemia Major (TM) 
patients.79 There are some factors leading to a 
reduction of bone density in TM, one of them could 
be mutations in gene for I collagen type, COLIAI.80 I 
collagen type is the most abundant protein in bone 
matrix. Polymorphism of the gene is associated with 
bone mineral density (BMD). Mutation in SP1 
binding site (G>T mutation) is reported as having a 
strong association with osteoporosis in TM patients. A 
study revealed that 19% of β thalassemia patients 
have a homozygous (G/G) genotype, 40% are 
heterozygous (T/G) and 43% are homozygous (T/T) 
genotype.81 
Hyperbilirubinemia and a propensity to the 
gallstones formation are general complications of β 
thalassemia patients. The complication is caused by 
ineffective erythropoiesis and shortening of the 
erythrocyte age. TA sequence polymorphism in the 
gene promoter of uridine diphosphate-
glucuronosyltransferase 1A (UGT1A), where the 
product is involved in bilirubin glucoronidation inside 
the liver also plays a role in the formation of 
gallstones.82 In normal individuals, the UGT1A gene 
promoter has six replications of TA (TA 6). 
Individuals with seven replications (TA 7) tend to 
have high level of bilirubin. Thalassemia patients with 
this polymorphism have a high propensity to form a 
gallstone.83  
β Thalassemia patients, especially major and 
intermedia can develop complications in adult state 
such as hypercoagulable states, including deep venous 
thrombosis and pulmonary embolism as well as 
arterial thrombosis and stroke.84 Study also reported 
that Thromboembolic events (TEE) were frequently 
developed in splenectomized patients.85 Genetics 
features involeved in TEE should be considered such 
as Factor V Leiden (FVL) rs6025, Prothrombin 
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G20210A rs1799963, PAI-1 -675 4G/5G, and 
MTHFR mutations.86 
The interaction with the gene mutation that causes 
a deficiency of pyrimidine-5 nucleotides-I (P5N-I) 
can cause a severe hemolytic anemia due to the 
susceptibility of the individual to free radicals.87 In 
addition, clinical complications of ß thalassemia 
patients is also affected by a set of genes related to 
iron metabolism such as Human hemochromatosis 
(HFE), transferrin receptor 2 (TFR2), ferroportin 
(FPN), Hepcidin (HAMP) and Hemojuvelin (HJV) 
genes.88  
  
CONCLUSION 
The studies of the genetic modifiers in thalassemia 
have been growing very rapidly. Some of the latest 
findings have good impactin clinical practices. The 
research on genetic of β thalassemia was needed for 
improvement in management patient in the 
future.MGP investigation should be done in high risk 
couples to predict whether the newbornwill have mild 
or severe clinical manifestation. 
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